T
Teru Hideshima
Researcher at Harvard University
Publications - 525
Citations - 52547
Teru Hideshima is an academic researcher from Harvard University. The author has contributed to research in topics: Bortezomib & Multiple myeloma. The author has an hindex of 117, co-authored 508 publications receiving 49767 citations. Previous affiliations of Teru Hideshima include Fukuoka University & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal Article
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Teru Hideshima,Paul G. Richardson,Dharminder Chauhan,Vito J. Palombella,Peter J. Elliott,Julian Adams,Kenneth C. Anderson +6 more
TL;DR: It is demonstrated that the proteasome inhibitor PS-341 both acts directly on MM cells and alters cellular interactions and cytokine secretion in the BM millieu to inhibit tumor cell growth, induce apoptosis, and overcome drug resistance.
Journal ArticleDOI
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Faith E. Davies,Noopur Raje,Noopur Raje,Noopur Raje,Teru Hideshima,Teru Hideshima,Teru Hideshima,Suzanne Lentzsch,Suzanne Lentzsch,Suzanne Lentzsch,Gloria Young,Gloria Young,Gloria Young,Yu-Tzu Tai,Yu-Tzu Tai,Yu-Tzu Tai,Boris Lin,Boris Lin,Boris Lin,Klaus Podar,Klaus Podar,Klaus Podar,Deepak K. Gupta,Deepak K. Gupta,Deepak K. Gupta,Dharminder Chauhan,Dharminder Chauhan,Dharminder Chauhan,Steven P. Treon,Steven P. Treon,Steven P. Treon,Paul G. Richardson,Paul G. Richardson,Paul G. Richardson,Robert L. Schlossman,Robert L. Schlossman,Robert L. Schlossman,Gareth J. Morgan,Gareth J. Morgan,Gareth J. Morgan,George W. Muller,George W. Muller,George W. Muller,David I. Stirling,David I. Stirling,David I. Stirling,Kenneth C. Anderson,Kenneth C. Anderson,Kenneth C. Anderson +48 more
TL;DR: In vitro and in vivo data support the hypothesis that Thal may mediate its anti-MM effect, at least in part, by modulating NK cell number and function.
Journal ArticleDOI
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima,Dharminder Chauhan,Dharminder Chauhan,Yoshihito Shima,Yoshihito Shima,Noopur Raje,Noopur Raje,Faith E. Davies,Faith E. Davies,Yu-Tzu Tai,Yu-Tzu Tai,Steven P. Treon,Steven P. Treon,Boris Lin,Boris Lin,Robert L. Schlossman,Robert L. Schlossman,Paul G. Richardson,Paul G. Richardson,George W. Muller,George W. Muller,David I. Stirling,David I. Stirling,Kenneth C. Anderson,Kenneth C. Anderson +24 more
TL;DR: Clinical activity of Thal against MM that is refractory to conventional therapy is demonstrated and mechanisms of anti-tumor activity of thalidomide and its potent analogs (immunomodulatory drugs [IMiDs]) are delineated.
Journal ArticleDOI
NF-κB as a Therapeutic Target in Multiple Myeloma *
Teru Hideshima,Dharminder Chauhan,Paul G. Richardson,Constantine S. Mitsiades,Nicholas Mitsiades,Toshiaki Hayashi,Nikhil C. Munshi,Lenny Dang,Alfredo C. Castro,Vito Palombella,Julian Adams,Kenneth C. Anderson +11 more
TL;DR: These studies demonstrate that specific targeting of NF-κB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu.